AIM ImmunoTech Inc. Converts ~$400K Debt into 1.75M Shares

What Happened

• AIM ImmunoTech Inc. announced that on September 8–9, 2026 it entered into two exchange agreements and corresponding partitioned promissory notes with Streeterville Capital, LLC to convert a portion of a promissory note dated November 18, 2025.
• Approximately $400,000 of the outstanding promissory note was converted into 1,749,434 shares of the company’s common stock at an average conversion price of about $0.228 per share. Stockholder approval for conversion or other satisfaction of the promissory note was previously obtained at a special meeting on July 15, 2026 under NYSE American rules.

Key Details

• Lender: Streeterville Capital, LLC.
• Amount converted: ~$400,000 of the November 18, 2025 promissory note.
• Shares issued: 1,749,434 common shares; average conversion price ≈ $0.228/share.
• Dates: Exchange agreements entered September 8–9, 2026; prior stockholder approval on July 15, 2026.
• The Form of Exchange Agreement is filed as Exhibit 10.1; the filing also references unregistered sales of equity securities (Item 3.02).

Why It Matters

• Debt reduction: Converting debt to equity reduces the company’s outstanding debt obligations without immediate cash outflow.
• Shareholder impact: Issuing 1.75M new shares increases the share count and is dilutive to existing shareholders, which can affect per-share metrics (e.g., EPS) and ownership percentages.
• Governance/compliance: The conversion followed prior stockholder approval required by NYSE American rules, and the exchange agreement is included in the 8-K, providing investors access to the full terms.